Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia

Leukemia

Volumn 11, Issue 10, 1997, Pages 1631-1635

  O'Brien', S ^a,b   Kantarjian, H ^a   Beran, M ^a   Koller, C ^a   Talpaz, M ^a   Lerner, S ^a   Keating, M J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CLL; Fludarabine; G CSF; Infections; Myelosuppression

Indexed keywords

FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGE; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; FEVER; GRANULOCYTE; HIGH RISK PATIENT; HUMAN; HYPERGAMMAGLOBULINEMIA; INFECTION; LEUKOCYTE COUNT; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030696074     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400816     Document Type: Article

References (22)

1. Bunch C. Management of infection in chronic lymphocytic leukemia. In: Gale RP, Rai KR (eds). Chronic Lymphocytic Leukemia: Recent Prognosis, Future Advances. Alan R Liss: New York, 1987, pp 373-381.
2. Briggs PC, Kraft N, Atkins RC. T-lymphocyte response to cytokines in B-chronic lymphocytic leukemia. Leuk Res 1991; 15: 859-865.
3. Prieto A, Carcia-Suarez J, Reyes E, Lapena P, Hernandez M, Alvarez-Mon M. Diminished DNA synthesis in T-cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals. Exp Hematol 1993; 21: 1563-1569.
4. Chapel HM, Bunch C. Mechanisms of infection in chronic lymphocytic leukemia. Semin Hematol 1987; 24: 291-296.
5. Rozman C, Montserrat E, Vinolas N. Serum immunoglobulins in B-CLL. Natural history and prognostic significance. Cancer 1988; 61:279-283.
6. Itala M, Helenius H, Nikoskelaien J, Remes K. Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur J Hematol 1992; 48: 266-270.
7. Copson ER, Ellis BA, Westwood NB, Majumdar G. IgG subclass levels in patients with B cell chronic lymphocytic leukemia. Leuk Lymphoma 1994; 14: 471-173.
8. Heiner DC, Myers A, Beck CS. Deficiency of lgG4: a disorder associated with frequent infections and bronchiectasis that may be familial. Clin Rev Allergy 1983; 1: 259-266.
9. Robertson TI. Complications and causes of death in B-cell chronic lymphocytic leukemia. Aust NZ J Med 1990; 20: 44-50.
10. Beck OE. Distribution of virus antibody activity among human IgG subclasses. Clin Exp Immunol 1981; 43: 626-632.
11. Arnold C, McPhedran P. Prognostic significance of neutrophil counts, gammaglobulin levels and symptoms in chronic lymphocytic leukemia. Blood 1985; 66: 170a.
12. + cells in the pathogenesis of neutropenia in patients with B-cell chronic lymphocytic leukemia. Eur J Hematol 1995; 55: 33-41.
13. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysisderived prognostic model for response to treatment. Blood 1993; 82: 1695-1700.
14. Bergmann L, Fenchel K, Jahn B, Mitrou PS, Hoelzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993; 4:371-375.
15. Wijermans PW, Gerrits WBJ, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Hematol 1993; 50: 292-296.
16. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. New Engl J Med 1988; 318: 1414-1422.
17. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with smallcell lung cancer. New Engl J Med 1991; 325: 164-170.
18. Pettengell R, Gurney H, Radford JA, Deakin DP, Jones R, Wilkinson PM et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430-1436.
19. Kurzrock R, Talpaz M, Gomez JA, Estey EH, O'Brien S, Hirsch-Ginsberg C et al. Differential dose-related hematologfcal effects of GM-CSF in pancytopenia: evidence supporting the advantage of low over high-dose administration in selected patients. Br J Haematol 1991; 78: 352-358.
20. Hollander AAMJ, Kluin-Nelemans HC, Haak HR, Stern AC, Willemze R, Fibbe WE. Correction of neutropenia associated with chronic lymphocytic leukemia following treatment with granulocyte-macrophage colony-stimulating factor. Ann Hematol 1991; 62: 32-34.
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma 1994; 13: 203-214.